Following the closing of the acquisition of KELIX bio, Mubadala Funding Firm PJSC has empowered its new specialty pharmaceutical enterprise to amass a 100% stake in 4 of GlobalOne Healthcare Holding’s (GHH) pharma property which embody Bioventure, Bioventure Healthcare, Gulf Inject and Wellpharma.
This strategic transfer consolidates Mubadala’s presence within the life sciences ecosystem, advances the UAE’s life sciences sector, and positions the nation as a world trade chief whereas supporting financial diversification.
In March 2024, Mubadala entered right into a definitive settlement to amass KELIX bio, a specialty pharmaceutical enterprise centered on delivering advanced generics throughout rising markets. The acquisition was efficiently closed final September.
GHH’s pharma property embody cutting-edge biopharma and IV options manufacturing. Integrating these property into KELIX bio’s ecosystem considerably advances their expanded capabilities. Every asset brings distinctive strengths to the portfolio.
Dr. Bakheet Al Katheeri, Chief Government Officer of UAE Investments Platform at Mubadala, acknowledged, “The fast completion of the KELIX bio acquisition and this subsequent transaction display our dedication to constructing a thriving life sciences sector within the UAE and supporting our nation’s ambition for a knowledge-based financial system.
We proceed to hunt partnerships and investments that align with our strategic targets, as we intention to generate worth for our stakeholders whereas strengthening the UAE’s place on this essential international trade. KELIX bio and its property are effectively positioned for accelerated progress and can allow us to ship on our ambition of making a regional life sciences champion.”
Ismail Ali Abdulla, Head of UAE Clusters, at Mubadala’s UAE Investments Platform, mentioned, “This acquisition reinforces our strategic intent to place the UAE on the forefront of the life sciences ecosystem on a world scale. It contributes to our nation’s financial diversification, creates helpful socio-economic returns, and reaffirms Mubadala’s ambitions throughout the sector.”
He added, “Being a accountable investor we proceed to nurture future-centric options that increase our nation’s GDP, enhance job creation, foster innovation, and strengthen medical safety, shaping the way forward for our communities with lasting impression.”
Hocine Sidi Mentioned, CEO of KELIX bio, mentioned, “The acquisition of GHH property significantly strengthens our presence within the UAE and offers us entry to a larger pipeline of merchandise and applied sciences. Bringing these companies and their colleagues into the KELIX bio community is thrilling because it accelerates our path to turning into a world life science chief.”
Low Ping, Group CEO Yas Holding, commented, “Divesting these subsidiaries to KELIX bio marks a strategic pivot for Yas Holding. This determination aligns with our dedication to enhancing healthcare entry and innovation throughout the area. We’re assured that underneath KELIX bio’s stewardship, Wellpharma, Gulf Inject, Bioventure Healthcare, and Bioventure will proceed to thrive and contribute considerably to the healthcare panorama. We look ahead to witnessing their continued progress and the constructive impression they are going to have on the life science sector at giant.”
The acquisition of 4 GHH property by KELIX Bio considerably enhances the UAE’s native life sciences capabilities by means of strategic investments.
This transfer aligns with authorities initiatives akin to ‘Operation 300bn’ and ‘Make it within the Emirates’, which intention to strengthen the nation’s manufacturing sector.
These acquisitions advance Mubadala’s efforts to ascertain a nationwide pharma champion based mostly in Abu Dhabi. They improve the UAE’s pharmaceutical infrastructure, handle prevalent ailments, safe drug provide, cut back healthcare prices, and progress the nation towards a knowledge-based financial system.
GlobalOne Healthcare Holding LLC (GHH) serves because the devoted Healthcare Division of Yas Holding LLC, specializing in enhancing healthcare outcomes by investing in biopharmaceuticals and healthcare providers.
Comply with Emirates 24|7 on Google Information.